Guan X - Search Results

1

Fulvestrant 500 mg Versus Exemestane in Postmenopausal Women With Metastatic Breast Cancer Resistant to Adjuvant Nonsteroidal Aromatase Inhibitors in Clinical Practice: A Multicenter Retrospective Study.

Xie Y, Li Y, Zhang Y, Zhang S, Li W, Guan X, Zhao Y, Gong C, Hu X, Zhang J, Cao E, Wang L, Ge R, Wang B. Xie Y, et al. Among authors: guan x. Clin Breast Cancer. 2019 Jun;19(3):e452-e458. doi: 10.1016/j.clbc.2019.01.015. Epub 2019 Feb 7. Clin Breast Cancer. 2019. PMID: 30846408 Free article.

2

Multitargeted antiangiogenic tyrosine kinase inhibitors combined to chemotherapy in metastatic breast cancer: a systematic review and meta-analysis.

Wang Z, Wang M, Yang F, Nie W, Chen F, Xu J, Guan X. Wang Z, et al. Among authors: guan x. Eur J Clin Pharmacol. 2014 May;70(5):531-8. doi: 10.1007/s00228-014-1654-5. Epub 2014 Feb 23. Eur J Clin Pharmacol. 2014. PMID: 24562632

3

Mechanisms of resistance to selective estrogen receptor down-regulator in metastatic breast cancer.

Huang D, Yang F, Wang Y, Guan X. Huang D, et al. Among authors: guan x. Biochim Biophys Acta Rev Cancer. 2017 Aug;1868(1):148-156. doi: 10.1016/j.bbcan.2017.03.008. Epub 2017 Mar 23. Biochim Biophys Acta Rev Cancer. 2017. PMID: 28344099 Review.

4

Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer.

Fang H, Huang D, Yang F, Guan X. Fang H, et al. Among authors: guan x. Breast Cancer Res Treat. 2018 Apr;168(2):287-297. doi: 10.1007/s10549-017-4612-y. Epub 2017 Dec 13. Breast Cancer Res Treat. 2018. PMID: 29236235 Review.

5

PAI-1 induces Src inhibitor resistance via CCL5 in HER2-positive breast cancer cells.

Fang H, Jin J, Huang D, Yang F, Guan X. Fang H, et al. Among authors: guan x. Cancer Sci. 2018 Jun;109(6):1949-1957. doi: 10.1111/cas.13593. Epub 2018 May 7. Cancer Sci. 2018. PMID: 29601121 Free PMC article.

6

T1-2N0M0 Triple-Negative Breast Cancer Treated With Breast-Conserving Therapy Has Better Survival Compared to Mastectomy: A SEER Population-Based Retrospective Analysis.

Li H, Chen Y, Wang X, Tang L, Guan X. Li H, et al. Among authors: guan x. Clin Breast Cancer. 2019 Dec;19(6):e669-e682. doi: 10.1016/j.clbc.2019.05.011. Epub 2019 May 30. Clin Breast Cancer. 2019. PMID: 31375327

7

Circulating Tumor DNA as a Novel Biomarker Optimizing Treatment for Triple Negative Breast Cancer.

Sun Y, Zhu C, Xu F, Cui S, Guan X. Sun Y, et al. Among authors: guan x. Clin Breast Cancer. 2023 Jun;23(4):339-349. doi: 10.1016/j.clbc.2023.02.012. Epub 2023 Mar 2. Clin Breast Cancer. 2023. PMID: 36966079 Review.

8

Cuproptosis engages in c-Myc-mediated breast cancer stemness.

Wang R, Xu K, Chen Q, Hu Q, Zhang J, Guan X. Wang R, et al. Among authors: guan x. J Transl Med. 2023 Jun 23;21(1):409. doi: 10.1186/s12967-023-04204-5. J Transl Med. 2023. PMID: 37353799 Free PMC article.

9

[Current opinions on the treatment of androgen-independent prostate cancer].

Guan XX, Chen LB. Guan XX, et al. Zhonghua Nan Ke Xue. 2006 Nov;12(11):1021-5. Zhonghua Nan Ke Xue. 2006. PMID: 17146932 Review. Chinese.

10

Trastuzumab enhances the anti-tumor effects of the histone deacetylase inhibitor sodium butyrate on a HER2-overexpressing breast cancer cell line.

Chen W, Wei F, Xu J, Wang Y, Chen L, Wang J, Guan X. Chen W, et al. Among authors: guan x. Int J Mol Med. 2011 Dec;28(6):985-91. doi: 10.3892/ijmm.2011.790. Epub 2011 Sep 1. Int J Mol Med. 2011. PMID: 21887460

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,557 results

Search Page

Filters